Combination therapy with csDMARDs in TNFi-INT/IR patients | Monotherapy in MTX-INT/IR patients | ||||
---|---|---|---|---|---|
Change in HbA1c at week 24 | Placebo + csDMARDs | Sarilumab 150 mg q2w + csDMARDs | Sarilumab 200 mg q2w + csDMARDs | Adalimumab 40 mg q2w monotherapy | Sarilumab 200 mg q2w monotherapy |
Patients with a medical history of diabetes or baseline use of antidiabetic medication | |||||
Number | 15 | 16 | 15 | 14 | 6 |
Baseline mean (SD) | 7.20 (1.06) | 6.94 (1.08) | 6.96 (1.09) | 6.77 (0.89) | 6.65 (1.17) |
LS mean change (SE)a | 0.23 (0.11) | − 0.24 (0.11) | − 0.44 (0.11) | 0.15 (0.11) | − 0.28 (0.16) |
LS mean difference, 95% CIa | − 0.47 (− 0.77, − 0.17) | − 0.67 (− 0.98, − 0.37) | − 0.43 (− 0.80, − 0.05) | ||
p value vs. placebo/adalimumaba | 0.0021 | < 0.0001 | 0.0257 | ||
Baseline HbA1c ≥ 7.0% | |||||
Number | 11 | 10 | 9 | 6 | 4 |
Baseline mean (SD) | 7.80 (0.58) | 7.77 (0.59) | 7.88 (0.61) | 7.57 (0.49) | 7.78 (0.54) |
LS mean change (SE)a | − 0.08 (0.13) | − 0.56 (0.13) | − 0.77 (0.14) | 0.29 (0.16) | − 0.67 (0.20) |
LS mean diff, 95% CIa | − 0.48 (− 0.84, − 0.12) | − 0.69 (− 1.06, − 0.32) | − 0.96 (− 1.46, − 0.46) | ||
p value vs. placebo/adalimumaba | 0.0097 | 0.0003 | 0.0002 |